World Investment Advisors LLC bought a new position in Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 103,912 shares of the company's stock, valued at approximately $23,389,000. World Investment Advisors LLC owned approximately 0.05% of Cencora at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. New Millennium Group LLC acquired a new position in Cencora during the 2nd quarter valued at approximately $26,000. MFA Wealth Advisors LLC acquired a new position in Cencora during the 2nd quarter worth $30,000. Concord Wealth Partners acquired a new position in Cencora during the 3rd quarter worth $30,000. SYSTM Wealth Solutions LLC acquired a new position in Cencora during the 2nd quarter worth $36,000. Finally, Ashton Thomas Securities LLC acquired a new position in Cencora during the 3rd quarter worth $41,000. Institutional investors and hedge funds own 97.52% of the company's stock.
Cencora Trading Down 0.4 %
Shares of Cencora stock traded down $0.90 on Friday, reaching $243.41. 1,199,812 shares of the company were exchanged, compared to its average volume of 1,126,541. The stock has a fifty day moving average price of $237.12 and a 200-day moving average price of $233.57. The firm has a market capitalization of $47.05 billion, a price-to-earnings ratio of 32.41, a price-to-earnings-growth ratio of 1.65 and a beta of 0.45. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $253.27.
Cencora Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.90%. This is a positive change from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora's payout ratio is presently 29.29%.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Leerink Partners reduced their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Finally, Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $276.80.
View Our Latest Report on COR
Insider Activity at Cencora
In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 93,018 shares of company stock valued at $22,478,942. Company insiders own 15.80% of the company's stock.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
